Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
An imbalance in gene activity in two types of immune cells explains why lung fibrosis after a severe COVID-19 infection doesn ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...
Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback